Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon Candida Species Collected in 2012: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values

Mycopathologia

Volumn 178, Issue 1-2, 2014, Pages 1-9

  Castanheira, Mariana ^a   Messer, Shawn A ^a   Rhomberg, Paul R ^a   Dietrich, Rachel R ^a   Jones, Ronald N ^a   Pfaller, Michael A ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Candida; Isavuconazole; Surveillance; Susceptibility

Indexed keywords

CANDIDA; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; ISSATCHENKIA ORIENTALIS; PICHIA GUILLIERMONDII;

ANTIFUNGAL AGENT; FUNGAL DNA; ISAVUCONAZOLE; NITRILE; PYRIDINE DERIVATIVE; RIBOSOMAL SPACER DNA; RIBOSOME DNA; RNA 28S; TRIAZOLE DERIVATIVE;

CANDIDA; CANDIDIASIS; CHEMISTRY; CLASSIFICATION; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HEALTH; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DNA, FUNGAL; DNA, RIBOSOMAL; DNA, RIBOSOMAL SPACER; GLOBAL HEALTH; HUMANS; MICROBIAL SENSITIVITY TESTS; NITRILES; PYRIDINES; RNA, RIBOSOMAL, 28S; SEQUENCE ANALYSIS, DNA; TRIAZOLES;

EID: 84904392677     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-014-9772-2     Document Type: Article

References (47)

1. Ha YE, Peck KR, Joo EJ, et al. Impact of first-line antifungal agents on the outcomes and costs of candidemia. Antimicrob Agents Chemother. 2012;56: 3950-6.
2. Lepak A, Andes D. Fungal sepsis: optimizing antifungal therapy in the critical care setting. Crit Care Clin. 2011;27: 123-47.
3. Pakyz AL, Gurgle HE, Oinonen MJ. Antifungal use in hospitalized adults in U. S. academic health centers. Am J Health Syst Pharm. 2011;68: 415-8.
4. Posteraro B, Posteraro P, Sanguinetti M. Update on antifungal resistance and its clinical impact. Curr Fungal Infect Rep. 2013; (in press).
5. Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013;62: 10-24.
6. Wilke M. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. Eur J Med Res. 2011;16: 180-6.
7. Auberger J, Lass-Florl C, Aigner M, Clausen J, Gastl G, Nachbaur D. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. J Antimicrob Chemother. 2012;67: 2268-73.
8. Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7): 19-37.
9. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48: 503-35.
10. Ullmann AJ, Akova M, Herbrecht R, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18(Suppl 7): 53-67.
11. Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56: 1724-32.
12. Arendrup MC, Dzajic E, Jensen RH, et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect. 2013;19: E343-53.
13. Borman AM, Szekely A, Palmer MD, Johnson EM. Assessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United Kingdom. J Clin Microbiol. 2012;50: 2639-44.
14. Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis. 2011;11: 142-51.
15. Miceli MH, Lee SA. Emerging moulds: epidemiological trends and antifungal resistance. Mycoses. 2011;54: e666-78.
16. Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis. 2011;17: 1855-64.
17. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004;42: 4419-31.
18. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol. 2010;48: 2373-80.
19. Sun HY, Singh N. Characterization of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents. 2010;35: 211-8.
20. Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther. 2009;7: 981-98.
21. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles of opportunistic yeast and mould clinical isolates (2010-2011); Application of new CLSI clinical breakpoints and epidemiological cutoff values to characterize geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013; (in press).
22. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, to 2012. J Clin Microbiol. 2010;2012(50): 2846-56.
23. Castanheira M, Woosley LN, Diekema DJ, Jones RN, Pfaller MA. Candida guilliermondii and other species of Candida misidentified as Candida famata: assessment by Vitek2, ITS sequence analysis and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry in two global surveillance programs. J Clin Microbiol. 2013;51: 117-24.
24. Johnson EM. Rare and emerging Candida species. Curr Fungal Infect Rep. 2009;3: 152-9.
25. Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program. Mycopathologia. 2012;174: 259-71.
26. Thompson GR 3rd, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia. 2010;170: 291-313.
27. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1, 007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008;52: 1396-400.
28. Guinea J, Recio S, Escribano P, Pelaez T, Gama B, Bouza E. In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. Antimicrob Agents Chemother. 2010;54: 4012-5.
29. Illnait-Zaragozi MT, Martinez GF, Curfs-Breuker I, Fernandez CM, Boekhout T, Meis JF. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother. 2008;52: 1580-2.
30. Perkhofer S, Lechner V, Lass-Florl C. In vitro activity of isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2009;53: 1645-7.
31. Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M. In vitro activity of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol. 2013;51: 2608-16.
32. Rudramurthy SM, Chakrabarti A, Geertsen E, Mouton JW, Meis JF. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagn Microbiol Infect Dis. 2011;71: 370-7.
33. Seifert H, Aurbach U, Stefanik D, Cornely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother. 2007;51: 1818-21.
34. Thompson GR 3rd, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother. 2009;64: 79-83.
35. Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat. 2009;12: 141-7.
36. Howell SA, Hazen KC. Candida, Cryptococcus, and other yeasts of medical importance. In: Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW, editors. Manual of clinical microbiology. 10th ed. Washington: ASM Press; 2011. p. 1793-821.
37. Larone DH. Medically important fungi: a guide to identification. 4th ed. Washington: ASM Press; 2002.
38. CLSI. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
39. CLSI. M27-S4. Reference method for broth dilution antifungal susceptibility testing of yeasts: 4th informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
40. Pfaller MA, Messer SA, Boyken L, et al. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13, 338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods. J Clin Microbiol. 2007;45: 70-5.
41. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol. 2008;46: 551-9.
42. Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation. 2005;80: 868-71.
43. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39: 743-6.
44. Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol. 2006;44: 529-35.
45. Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol. 2006;44: 1740-3.
46. Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother. 1999;43: 2753-65.
47. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005;49: 668-79.